Contemporary management of rectal cancer includes consideration of adjuvant anti EGFR therapy; however, KRAS mutational status profiling is mandatory prior to initiation of this therapy. KRAS mutational status is typically assayed on tissue samples (biopsy/surgical specimens). Radiomic features have demonstrated the ability to quantitatively characterize image phenotypic appearance associated with genotype expression in different tumors. We explored the utility of multi-scale, multi-oriented filter banks to define radiomics signatures that distinguish KRAS mutated vs wildtype tumors on T2W MRI. Initial results indicate that macro-scale radiomic features depict significantly different responses between the 2 genotypic groups.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords